Troglitazone, a TZD used as an insulin-sensitizing drug for patients with T2DM, has been withdrawn in some markets, such as the United States, due to reports that the drug is associated with liver toxicity [42]. This evidence concerns the gene INS and type 2 diabetes mellitus.